Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men who have been diagnosed with prostate cancer (a specific type called adenocarcinoma) confirmed through a prostate biopsy
- Men who have had prostate cancer come back in the same area (local recurrence), confirmed by biopsy and standard imaging tests that show the cancer has not spread to nearby lymph nodes or other parts of the body
- People aged between 18 and 90 years old
- People with a life expectancy of more than one year
- People who are able to understand the study information and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- People whose anatomy makes it physically impossible to perform a targeted ablation (tissue destruction) treatment
- People whose cancer has spread beyond the prostate in a way that cannot be treated with ablation
- People who currently have an active urinary tract infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel Segal, M.D., University of Texas Southwestern Medical Center
Phone: 214/645-8482
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Oncologic outcomes as assessed by the rate of negative in-field biopsy at 12 months (primary setting); Oncologic outcomes as assessed by the rate of advancement to systemic therapy or radical salvage therapies (primary setting); Oncologic outcomes as assessed by the rate of negative in-field biopsy at 12 months (salvage setting); Oncologic outcomes as assessed by the rate of progression to systemic therapy or radical salvage therapies (salvage setting); Change in urinary function as measured by International Prostate Symptom Score (IPSS) questionnaire (primary setting); Change in urinary funct...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.